$9.63
-0.270 (-2.73%)
At Close: Jun 03, 2026
5 Penny Stocks To Buy Now According To Insiders
12:52pm, Wednesday, 15'th Nov 2023
Penny stocks are often priced under $5 per share. They attract traders seeking big gains.
Atara Biotherapeutics: Market Overreaction To Failed MS Study Creates Buy Opportunity
02:13am, Monday, 13'th Nov 2023
Atara Biotherapeutics stock price dropped by 80% following failure of ATA188 in a phase 2 study in multiple sclerosis. This was an excessive reaction by the market in my opinion. ATRA's restructuring,
Atara Biotherapeutics, Inc. (ATRA) Q3 2023 Earnings Call Transcript
11:45am, Saturday, 04'th Nov 2023
Atara Biotherapeutics, Inc. (NASDAQ:ATRA ) Q3 2023 Results Conference Call November 1, 2023 9:00 AM ET Company Participants Alex Chapman - VP, Corporate Communications & IR Dr. Pascal Touchon - Presid
Atara (ATRA) Up 11% on Regulatory Update From Blood Cancer Study
10:31am, Thursday, 21'st Sep 2023
Atara (ATRA) rises 11% on an update regarding the regulatory pathway for the company's lead product candidate, tab-cel, in the treatment of a rare, deadly and hematologic malignancy.
Atara Biotherapeutics (ATRA) Reports Q2 Loss, Lags Revenue Estimates
06:56pm, Tuesday, 08'th Aug 2023
Atara Biotherapeutics (ATRA) came out with a quarterly loss of $0.68 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to loss of $0.31 per share a year ago.
Atara Biotherapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
04:01pm, Wednesday, 07'th Jun 2023
THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell pl
Atara Biotherapeutics (ATRA) Reports Q1 Loss, Lags Revenue Estimates
07:02pm, Monday, 08'th May 2023
Atara Biotherapeutics (ATRA) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.87 per share a year ago.
3 Stocks to Buy That Could Be the Next Biotech Breakthrough
12:08pm, Sunday, 16'th Apr 2023
In general, biotech stocks are not ideal for conservative investors. The companies in search of the next medical breakthrough are inherently risky.
Atara Biotherapeutics (ATRA) Reports Q4 Loss, Misses Revenue Estimates
06:49pm, Wednesday, 08'th Feb 2023
Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of -18.03% and 99.63%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the sto
Atara Biotherapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
04:01pm, Wednesday, 04'th Jan 2023
THOUSAND OAKS, Calif.--( BUSINESS WIRE )--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to deve
3 Under-the-Radar Biotech Stocks to Buy in 2022
10:07am, Saturday, 24'th Dec 2022
The attraction of all three biotech stocks is their potential.
Consider Atara Biotherapeutics As The Tab-Cel Delay Resolves In The U.S.
08:00am, Saturday, 17'th Dec 2022
Atara Biotherapeutics has complications with the FDA while the EU approach is so much clearer. The MS drug is a value driver if ATRA sorts out issues.
Atara Biotherapeutics, Inc. (ATRA) Q3 2022 Earnings Call Transcript
09:43pm, Tuesday, 08'th Nov 2022
Atara Biotherapeutics, Inc. (NASDAQ:ATRA ) Q3 2022 Results Conference Call November 8, 2022 4:30 PM ET Company Participants Eric Hyllengren - Vice President of Investor Relations and Finance Dr. Pasca
Atara Biotherapeutics (ATRA) Reports Q3 Loss, Tops Revenue Estimates
06:48pm, Tuesday, 08'th Nov 2022
Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of -5.13% and 2.13%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stoc
Best Penny Stocks To Buy? 5 Biotech Stocks For Your Watch List This Week
02:13pm, Monday, 24'th Oct 2022
Biotech penny stocks for your watch list this week. The post Best Penny Stocks To Buy?
Sign In
Buy ATRA